SAR342434

rapid-acting insulin lispro product

Networked: 4 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Pancreatic Hormones: 113
      - Insulins: 644
        Short-Acting Insulin: 400
        Insulin Lispro: 565
        SAR342434: 4
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Hormones: 1347
    - Pancreatic Hormones: 113
      - Insulins: 644
        Short-Acting Insulin: 400
        Insulin Lispro: 565
        SAR342434: 4

Experts

1.	Pierre, Suzanne: 2 articles (01/2018 - 01/2017)
2.	Wernicke-Panten, Karin: 2 articles (01/2018 - 01/2017)
3.	Hu, Jingbo: 1 article (11/2018)
4.	Wang, Min: 1 article (11/2018)
5.	Zhao, Yufen: 1 article (11/2018)
6.	Bailey, Timothy S: 1 article (01/2018)
7.	Derwahl, Karl-Michael: 1 article (01/2018)
8.	Ping, Lin: 1 article (01/2018)
9.	Becker, Reinhard H A: 1 article (01/2017)
10.	Bergmann, Karin: 1 article (01/2017)

Related Diseases

1.	Diabetes Mellitus 11/01/2018 - "These attributes show the good potential of SAR342434 for serving as an alternative to achieve the glycemic control in patients with diabetes mellitus." 11/01/2018 - "SAR342434 is a biosimilar follow-on of insulin lispro, a key therapeutic for the treatment of diabetes mellitus, and it is currently under phase III clinical trials. "
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/01/2017 - "In a single-centre, randomized, double-blind, 3-treatment, 3-period, 6-sequence, crossover, euglycaemic clamp study (NCT02273258), adult male subjects with type 1 diabetes were randomized to receive 0.3 U/kg of SAR342434 solution, US-approved and EU-approved Humalog under fasted conditions. " 01/01/2017 - "Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes." 01/01/2017 - "This study aimed to show similar efficacy, safety, and immunogenicity of SAR342434 (SAR-Lis) versus insulin lispro-Humalog (Ly-Lis) in adult patients with type 1 diabetes (T1DM) treated with multiple daily injections while using basal insulin glargine (Lantus®; GLA-100). " 01/01/2017 - "Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study."
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2018 - "Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study."

Related Drugs and Biologics

1.	Insulin Lispro (Humalog)
2.	Biosimilar Pharmaceuticals
3.	Insulin Glargine (Lantus)
4.	Solutions
5.	Short-Acting Insulin

Related Therapies and Procedures

1.	Injections
2.	Glycemic Control